aibio
Listings ·
Anavex regains Nasdaq compliance after filing overdue 10-Qs on August 28, 2026
Nasdaq says Anavex has regained compliance after filing overdue quarterly reports, but the release does not say why they were late.
AVXL Anavex Life Sciences Corp.
Anavex Life Sciences (AVXL) news AVXL offering and Nasdaq notice news
Latest Anavex Life Sciences news
- Distress
Anavex Life Sciences files NT 10-Q, says June quarter report is late amid special committee review
Anavex (Nasdaq: AVXL) cannot file its 10-Q for the quarter ended June 30, 2026 on time. The company also lists its 10-Q for the quarter ended March 31, 2026 as not yet filed.
- Distress
Anavex Life Sciences says it cannot file its June quarter report on time
The company cites a special committee's review of matters tied to the April 30, 2026 termination of its chief executive. Its quarterly report for the period ended March 31, 2026 is also listed as not filed.
- Distress
Anavex Life Sciences files late-filing notice for 10-Q after CEO termination
Anavex Life Sciences told the SEC on May 11, 2026 that it cannot file its first-quarter 10-Q on time. The delay follows the April 30 termination of CEO Christopher Missling, and the company says the review of that termination may take longer than it expects.
- Financings
Anavex signs at-the-market sales agreement with TD Cowen for up to $150 million
The company may sell common stock from time to time but is not obligated to sell any. TD Cowen can earn up to 3.0% in commissions.
Anavex Life Sciences annual financials
| Line | FY ended Sep 30, 2025 | FY ended Sep 30, 2024 |
|---|---|---|
| Research and development | $37.6 million | $41.8 million |
| Net income (loss) | -$46.4 million | -$43.0 million |
| Cash from operations | -$39.0 million | -$30.8 million |
| Cash and equivalents | $102.6 million | $132.2 million |
Questions about Anavex Life Sciences
Has Anavex Life Sciences raised money recently?
Our latest story on this, dated Jul 25, 2025: "Anavex signs at-the-market sales agreement with TD Cowen for up to $150 million". The story links the filing or release it is based on. Read the story.
Has Anavex Life Sciences received a Nasdaq deficiency notice?
Our latest story on this, dated May 11, 2026: "Anavex Life Sciences files late-filing notice for 10-Q after CEO termination". The story links the filing or release it is based on. Read the story.
What is the ticker symbol of Anavex Life Sciences?
Anavex Life Sciences Corp. trades under the ticker AVXL on NASDAQ.
Where is Anavex Life Sciences listed?
Anavex Life Sciences Corp. is listed on NASDAQ. Our directory also records these other listings: GETTEX:12X1; LS:A1411S; LSE:0HFR; LSX:A1411S.
What is the SEC CIK of Anavex Life Sciences?
The SEC Central Index Key (CIK) for Anavex Life Sciences Corp. is 1314052. Its filings are on SEC EDGAR.
How many shares does Anavex Life Sciences have outstanding?
92,696,842 shares as of 2026-08-28, per the cover page of its 10-Q filed 2026-08-28.
Which country or territory is Anavex Life Sciences listed under?
Our directory records Anavex Life Sciences Corp. under United States.
What does Anavex Life Sciences do?
Our directory classifies Anavex Life Sciences Corp. as: Biotechnology. This is a directory classification, not a description of the pipeline.
What is the ISIN of Anavex Life Sciences?
The ISIN recorded for Anavex Life Sciences Corp. is US0327973006.
Does aibio.space cover Anavex Life Sciences?
aibio.space lists Anavex Life Sciences Corp. among 2,820 public biotech companies and publishes its news here as stories appear.
Is Anavex Life Sciences profitable?
Anavex Life Sciences Corp. reported a net loss of $46.4 million for the fiscal year ended Sep 30, 2025, and used $39.0 million of cash in operations, per its annual report to the SEC.
How much does Anavex Life Sciences spend on research and development?
$37.6 million in the fiscal year ended Sep 30, 2025, per its annual report.
How much cash does Anavex Life Sciences have?
$118.3 million in cash at Jun 30, 2026, per its 10-Q.
What is the latest Anavex Life Sciences (AVXL) stock news?
Our latest story on Anavex Life Sciences, dated Sep 2, 2026: "Anavex regains Nasdaq compliance after filing overdue 10-Qs on August 28, 2026". Nasdaq says Anavex has regained compliance after filing overdue quarterly reports, but the release does not say why they were late. Source.
How long will Anavex Life Sciences's cash last?
From our story of May 11, 2026: The same report says Anavex has had a history of losses and no revenue, which raises a risk regarding its ability to continue as a going concern in the future, and that it had accumulated a deficit of approximately $382 million from inception through September 30, 2025. Source.
Investor discussion: Anavex Life Sciences
Rules
- Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
- Say whether you hold the stock. Every post states long, short or no position.
- No paid or sponsored posts. Do not post for anyone who pays or rewards you.
- No buy or sell calls and no price targets.
- No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
- No personal details and no spam. No links at all for your first 7 days as a member.
Capital-markets timeline
- Listings
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). Source
- Distress
Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. Source
- Listings
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). Source
- Listings
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,8.01,9.01). Source
- Distress
Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. Source
- Financings
Reported a financing. SEC Form 424B5. Source
- Legal
Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-K. Source
Stock chart
SEC filings and registration
- SEC name
- Anavex Life Sciences Corp.
- CIK
- 1314052
- Industry (SIC)
- Biological Products, (No Diagnostic Substances) (2836)
- US tickers
- AVXL (Nasdaq)
- Fiscal year ends
- September 30
- Filer category
- Large accelerated filer<br>Smaller reporting company
- Business address
- 630 5TH AVENUE, NEW YORK, NY, 10111
- Phone
- 844-689-3939
- Shares outstanding
- 92,696,842 as of 2026-08-28 (10-Q filed 2026-08-28)
- Former names
- Thrifty Printing Inc.
Recent filings
Listing details
- Company
- Anavex Life Sciences Corp.
- Ticker
- AVXL
- Listing
- NASDAQ
- Country or territory
- United States
- Business scope
- Biotechnology
- ISIN
- US0327973006
- Other listed symbols
- GETTEX:12X1; LS:A1411S; LSE:0HFR; LSX:A1411S
- Last quote in directory
- 2026-10-21
- Directory source
- Listing page
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction